AMGN250110C225000
- 38.40
- 0.000.00%
Amgen Newsroom
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $298
Amgen Analyst Ratings
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating, Announces Target Price $298
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $324
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK
Amgen's IMDYLLTRA▼ (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz